Large numbers of men could have missed a prostate cancer diagnosis due to Covid-19. Combine that with a rise in prostate cancer and the future looks grim. Ultimately, something in the prostate cancer diagnostic landscape needs to change: but what?
Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail’s Galleri test, which screens patients for more than 50 kinds of cancer.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.